Literature DB >> 35578145

Polypharmacy and potentially inappropriate medications in stroke rehabilitation: prevalence and association with outcomes.

Ayaka Matsumoto1, Yoshihiro Yoshimura2, Fumihiko Nagano3, Takahiro Bise3, Yoshifumi Kido3, Sayuri Shimazu4, Ai Shiraishi5.   

Abstract

Background Evidence is scarce regarding polypharmacy and potentially inappropriate medications (PIMs) in rehabilitation medicine. Aim To investigate the prevalence of polypharmacy and PIMs and their association with outcomes in stroke rehabilitation. Method A retrospective cohort study was conducted with 849 older inpatients post-stroke. Polypharmacy was defined as six or more medications, and PIMs were defined based on Beers criteria 2019. Study outcomes included functional independence measure (FIM)-motor, FIM-cognitive, energy intake, dysphagia, length of hospital stay, and the rate of home discharge. To consider the effect of pharmacotherapy during rehabilitation, multivariate analyses were used to determine whether the presence of polypharmacy or PIMs at discharge was associated with outcomes. Results After enrollment, 361 patients (mean age 78.3 ± 7.7 years; 49.3% male) were analyzed. Polypharmacy was observed in 43.8% and 62.9% of patients, and any PIMs were observed in 64.8% and 65.4% of patients at admission and discharge, respectively. The most frequently prescribed PIMs included antipsychotics, benzodiazepines, and proton pump inhibitors. Polypharmacy was negatively associated with FIM-motor score (β = - 0.062, P = 0.049), FIM-cognitive score (β = - 0.076, P = 0.014), energy intake (β = - 0.143, P = 0.005), and home discharge (OR: 0.458; 95% CI: 0.248, 0.847; P = 0.013). PIMs were negatively associated with home discharge (OR: 0.375; 95% CI: 0.195, 0.718; P = 0.003). Conclusion Polypharmacy and PIMs are commonly found among older patients undergoing stroke rehabilitation. Moreover, polypharmacy was negatively associated with activities of daily living (ADL) but not with PIMs and ADLs, and both were associated with home discharge.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Activities of daily living; Beers criteria; Geriatric rehabilitation; Multimorbidity; Polymedication; Potentially inappropriate medications

Mesh:

Year:  2022        PMID: 35578145     DOI: 10.1007/s11096-022-01416-5

Source DB:  PubMed          Journal:  Int J Clin Pharm


  49 in total

1.  The "iatrogenic triad": polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults.

Authors:  Priscila Horta Novaes; Danielle Teles da Cruz; Alessandra Lamas Granero Lucchetti; Isabel Cristina Gonçalves Leite; Giancarlo Lucchetti
Journal:  Int J Clin Pharm       Date:  2017-04-28

2.  Medication non-adherence among elderly patients newly discharged and receiving polypharmacy.

Authors:  L Pasina; A L Brucato; C Falcone; E Cucchi; A Bresciani; M Sottocorno; G C Taddei; M Casati; C Franchi; C D Djade; A Nobili
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

3.  Polypharmacy as a risk for fall occurrence in geriatric outpatients.

Authors:  Taro Kojima; Masahiro Akishita; Tetsuro Nakamura; Kazushi Nomura; Sumito Ogawa; Katsuya Iijima; Masato Eto; Yasuyoshi Ouchi
Journal:  Geriatr Gerontol Int       Date:  2011-12-23       Impact factor: 2.730

4.  Development of delirium: a prospective cohort study in a community hospital.

Authors:  N J Martin; M J Stones; J E Young; M Bédard
Journal:  Int Psychogeriatr       Date:  2000-03       Impact factor: 3.878

Review 5.  Clinical consequences of polypharmacy in elderly.

Authors:  Robert L Maher; Joseph Hanlon; Emily R Hajjar
Journal:  Expert Opin Drug Saf       Date:  2013-09-27       Impact factor: 4.250

Review 6.  Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review.

Authors:  Terri R Fried; John O'Leary; Virginia Towle; Mary K Goldstein; Mark Trentalange; Deanna K Martin
Journal:  J Am Geriatr Soc       Date:  2014-12       Impact factor: 5.562

7.  Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.

Authors:  Julie Doan; Hubert Zakrzewski-Jakubiak; Julie Roy; Jacques Turgeon; Cara Tannenbaum
Journal:  Ann Pharmacother       Date:  2013-03-12       Impact factor: 3.154

Review 8.  When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly.

Authors:  Klaus Turnheim
Journal:  Exp Gerontol       Date:  2003-08       Impact factor: 4.032

9.  Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well?

Authors:  Amaia Calderón-Larrañaga; Beatriz Poblador-Plou; Francisca González-Rubio; Luis Andrés Gimeno-Feliu; José María Abad-Díez; Alexandra Prados-Torres
Journal:  Br J Gen Pract       Date:  2012-12       Impact factor: 5.386

10.  Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population?

Authors:  Jacqueline L Green; Jonathan N Hawley; Kimberly J Rask
Journal:  Am J Geriatr Pharmacother       Date:  2007-03
View more
  2 in total

1.  Potentially inappropriate medications are negatively associated with functional recovery in patients with sarcopenia after stroke.

Authors:  Ayaka Matsumoto; Yoshihiro Yoshimura; Fumihiko Nagano; Sayuri Shimazu; Ai Shiraishi; Yoshifumi Kido; Takahiro Bise
Journal:  Aging Clin Exp Res       Date:  2022-08-29       Impact factor: 4.481

2.  The Applicability of the ESPEN and EASO-Defined Diagnostic Criteria for Sarcopenic Obesity in Japanese Patients after Stroke: Prevalence and Association with Outcomes.

Authors:  Yoshihiro Yoshimura; Hidetaka Wakabayashi; Fumihiko Nagano; Ayaka Matsumoto; Sayuri Shimazu; Ai Shiraishi; Yoshifumi Kido; Takahiro Bise
Journal:  Nutrients       Date:  2022-10-09       Impact factor: 6.706

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.